Event Impressions and some Key Quotes: Perfecting Partnerships for Life Sciences Startup Success
Closing a deal is more art than science. This is especially true in the biopharma industry where investments and partnerships are key elements to success. That is why, together with JLABS, BaseLaunch organized a panel of seasoned deal makers to discuss the nuts and bolts of the partnership process.
Stephan Emmerth, Sascha Bucher, Dominik Escher, Günter Huhle, Carole Nuechterlein, Markus Werner (ltr, img: Pino Covino)
Discussions particulary elaborated on the importance of making noise and selling your science, something which Americans are very good at while Europeans should try to be more outgoing. Especially because European science is on par with to its peers in the US. At the event, one piece of advice was: If you are trying to raise capital, don’t go to venture funds asking for 2 million francs to master the next baby steps. Investors are well aware of the capital intensiveness of the business and they don’t shy away from committing 20 million francs to get to the next real value inflection point.
The panel emphasized the relevance of conferences as a great platform to curate one’s network (although usually, deals are not closed there – with a notable exception, see below), and also covered deal-making discussion, venture financing, out-licensing and partnering. Stephan Emmerth, Director at Therapeutic Innovation and BaseLaunch, greatly enjoyed moderating the event and appreciates the time the panelists took afterwards to connect with the audience. Below you can find some key quotes captured during the event.
“Although most deals are not done in partnering conferences – except at JP Morgan – if you don’t go to any then you don’t exist! They help to increase visibility and strengthen deal muscles. However, small companies must make sure to have a Senior Business Development mentor with them enabling high value contacts, especially during the networking sessions.”
“Making a deal is a long-term process. You should start talking early, sometimes years before. During negotiations, the ability to get along with prospective partners is key to how a collaboration is going to work in the future. Quite frankly, if you don’t get along with your syndicate, it’s difficult!”
“Knowing the target and Mode of Action is absolutely crucial for investing in new treatments today. If the technology is just a black box that works without anyone knowing how and why, it’s very likely a no-go for most pharma and VC investors. Although some players might still do it, financing drug repurposing is not very attractive from the venture investment point of view – we are seeking to invest in new innovative treatments.”
“Every organization is different. While some companies have their out-licensing deals available on their website, others prefer not to disclose what is available and what isn’t. In any case, if you are serious about in-licensing a pharma asset, be prepared to demonstrate that you have the developmental and financial capabilities to further develop it.”
“You should always define the company strategy before searching for partners and making the deals. Learn from a partner’s behavior on a previous deal as it is a good indicator of how they will behave in the future: e.g. pragmatic vs slow. By watching carefully how the negotiation unfolds, you start to develop a feeling for what the alliance will become.”
To sum it up: don’t forget to be bold when the time comes for selling your technology. You will also need a great network, of course, and to know the key decision makers and internal corporate “champions” to help you find a place at the table and close the deal.
If you are an early-stage venture, you might consider an incubator or accelerator as they will provide the critical mass and the network needed to succeed. JLABS and BaseLaunch are providing an incubator and an accelerator in Beerse, Belgium as well in Basel. Check out the slides below to find out how they can support you and apply.
Thanks to all participants for the valuable input.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.Read More